Larvol Delta - Mateon-to-Develop-its-OT101-a-Phase-3-Clinical-Drug-Candidate-Initially-Against-COVID19

trabedersen (OT-101) - Autotelic, Mateon Therapeutics

http://www.globenewswire.com/news-release/2020/03/18/2002555/0/en/Mateon-to-Develop-its-OT-101-a-Phase-3-Clinical-Drug-Candidate-Initially-Against-COVID-19.html

Mar 18, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next